



Adequan® Canine polysulfated glycosaminoglycan (PSGAG) solution
100 mg/mL in a 5 mL preserved Multiple dose vial for intramuscular use in dogs.

Brief Summary: Prior to use please consult the product insert. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indications and Usage: Adequan Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. **Efficacy:** Efficacy of Adequan Canine was demonstrated in two studies, a laboratory study and a clinical field trial.

Contraindications: PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders or in dogs showing hypersensitivity to PSGAG.

Precautions: The safe use of Adequan Canine used in breeding, pregnant, or lactating dogs has not been evaluated. Use with caution in dogs with renal or hepatic impairment. **Adverse Reactions:** In the clinical efficacy trial, 24 dogs were treated with Adequan Canine twice weekly for 4 weeks. Possible adverse reactions were reported after 2.1% of the injections. These included transient pain at the injection site (1 incident), transient diarrhea (1 incident each in 2 dogs), and abnormal bleeding (1 incident). These effects were mild and self-limiting and did not require interruption of therapy.

Post Approval Experience (2014): The following adverse events are based on voluntary, post-approval reporting. The signs reported are listed in decreasing order of reporting frequency: vomiting, anorexia, depression/lethargy, and diarrhea. In some cases, death has been reported. **Warnings:** Not for use in humans. Keep this and all medications out of reach of children.

Dosage and Administration: Adequately clean and disinfect the stopper prior to entry with a sterile needle and syringe to decrease the possibility of post-injection bacterial infections. **Use only sterile needles, and use each needle only once. Use in 28 days of first puncture and puncture a maximum of 10 times.** This risk information is not comprehensive, visit adequancanine.com to obtain the FDA-approved product labeling. To report suspected adverse drug events, contact American Regent, Inc. at 1-888-354-4857



Adequan and the Dog Head design are trademarks of American Regent, Inc.

NAV C Gives: Recognizing the Good in Animal Health



The NAVC is guided by its vision of creating “a world in which the veterinary healthcare team thrives.” That vision spurred the establishment of NAVC Gives, a new award program created to support and advance the veterinary profession worldwide. The NAVC launched this program with a \$1 million commitment, which will be used for years to come to recognize individuals, groups, or unheralded organizations that support the NAVC’s mission and have made significant contributions to the profession or animal welfare. The inaugural recipients will be announced at VMX 2024.

“NAV C Gives is a unique grassroots award program that seeks to shine the light on those who are making a difference in the animal health field—whether it’s transforming

veterinary medicine or saving 1 animal or person in distress in a local veterinary clinic,” said Gene O’Neill, CEO of the NAVC. “In addition to recognizing these accomplishments, we hope to make an impact on a personal level with a cash award.”

NAV C Gives will recognize accomplishments and notable achievements throughout the year based on the value and impact of the nomination. Multiple awards of varying amounts may be given out each year, and recipients will be selected using a merit-based scale by a judging committee composed of the NAVC board members, staff, and other individuals from the animal healthcare industry.

Learn more about NAV C Gives and submit nominations at navc.com/gives.